Access TOC
Download Data
October 2024
The recombinant lysyl endopeptidase market was estimated at US$ 38 million in 2023 and is projected to grow to US$ 67.06 million by 2034, rising at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2034. The rising demand for proteomics and genetic engineering, increasing investments, and rising chronic illnesses drive the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Recombinant lysyl endopeptidase is an enzyme that hydrolyzes amide and peptide ester bonds at the carboxylic side of lysine and S-aminoethyl cysteine residues. Lysyl endopeptidase is mainly derived from three microorganisms, Achromobacter, Lysobacterium, and Pseudomonas aeruginosa. The natural form of the enzyme is not widely used due to its low yield, complex purification process, and long production cycle. However, the recombinant form resolves the issues, resulting in increased yield with high purification.
Recombinant lysyl endopeptidase is commonly used in proteomics, peptide sequencing, insulin preparation, identification of phosphorylated peptides, disulfide bond analysis, N-glycan analysis, and detection of glycated hemoglobin. The growing research and development and increasing R&D investments drive the market. The research areas like proteomics, genetic engineering, and personalized medicine increase the demand for recombinant lysyl endopeptidase. Additionally, the increasing cases of diabetes increase the demand for insulin, potentiating the market.
In September 2024, Sino Biological, a leading recombinant protein production company, announced a strategic partnership with BioGeometry, a pioneer in generative AI for protein design. The partnership will enhance Sino Biological’s advanced protein expression and wet lab capabilities with BioGeometry’s generative AI protein design and optimization platform.
The Chinese Government recently launched the π-HuB Consortium to invest in the development of new proteomic technologies, with a particular focus on single-cell proteomic and protein sequencing technologies. The project was made to develop computational models and tools for disease risk assessment, diagnosis, and treatment guidance.
Proteomics is the complete study of the function, interactions, composition, and structures of proteins to understand an organism's nature. Proteomics can aid in identifying different proteins and targets involved in a disease. It is also essential in novel drug discovery and identification of disease biomarkers. Additionally, proteomics gives ideas about protein-protein interactions, which are useful in cell signaling cascades and gene regulatory networks. Recombinant lysyl endopeptidase is an essential enzyme for proteomics research. The increasing incidences of chronic disorders, demand for novel drug discovery and development, diagnostics, and early identification of the disease potentiates the need for proteomics. This further leads to an increase in demand for recombinant lysyl endopeptidase.
The high cost of recombinant lysyl endopeptidase is a major restraint of the market. The average cost of the recombinant protein is around $350 to $500 per 20 μG. This limits the affordability of many laboratories and research institutions in lower- and middle-income countries.
North America dominated the recombinant lysyl endopeptidase market in 2023. The state-of-the-art research & development facilities, favorable capital investment, increasing awareness for proteomics and genetic engineering, and the presence of key players drive the market. Countries like the US and Canada are at the forefront of promoting the market. The US and Canadian government bodies like the National Institute of Standards and Technology and the National Cancer Institute support several initiatives regarding proteomics research.
The approval of novel drugs is higher in the region than in the rest of the world. The US FDA approved 37 new drugs in 2022 and 55 new drugs in 2023. The increasing investments in the biotechnology sector favor the growth of the market. Additionally, the increasing incidences of type 1 diabetes promote market growth. In 2022, the US reported the highest number of type 1 diabetes cases globally. Canada was also ranked among the top ten countries with the highest number of type 1 diabetes cases, accounting for approximately 300,000 cases.
Asia-Pacific is estimated to grow fastest in the recombinant lysyl endopeptidase market during the forecast period. The increasing incidences of chronic disorders, growing research & development activities, increasing number of patents, and rising awareness for proteomics, genetic engineering, and personalized medicines drive the market. India and China were ranked second and fourth, respectively, with the highest number of type 1 diabetes cases globally in 2022. According to the Indian Council of Medical Research (ICMR) report, around 95,600 children below the age of 14 years suffered from type 1 diabetes in 2022.
By type, the powder segment held a dominant presence in the market in 2023. The recombinant lysyl endopeptidase powder is highly preferred as it is stable and lightweight. It can be easily stored and transported, requiring less cost. Also, the requirement of minute quantity favors the use of powder form of the recombinant protein.
By application, the protein analysis segment held the largest share of the market in 2023. Recombinant lysyl endopeptidase is widely used in proteomics and protein identification. The increasing incidences of chronic disorders demand early detection and treatment of disease, necessitating a deeper understanding of disease prognosis. The increasing demand for proteomics and novel drug discovery research promotes segment growth.
By Type
By Application
By Region
October 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts